Integra Lifesciences Holdings (IART) Total Non-Current Liabilities (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Total Non-Current Liabilities data on file, last reported at $2.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 1.2% year-over-year to $2.3 billion; the trailing twelve-month figure through Mar 2026 stood at $2.3 billion (down 1.2% YoY), and the FY2025 full-year result was $2.4 billion, changed 0.36% from the prior year.
• Total Non-Current Liabilities retreated to $2.3 billion in Q1 2026, from $2.4 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $2.4 billion in Q2 2024 to a low of $1.9 billion in Q1 2023.
• A 5-year average of $2.2 billion and a median of $2.3 billion in 2026 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities fell 4.66% in 2022 and increased 22.89% in 2024, its largest moves.
• Tracing IART's Total Non-Current Liabilities over 5 years: stood at $2.1 billion in 2022, then fell by 3.21% to $2.0 billion in 2023, then grew by 17.64% to $2.3 billion in 2024, then advanced by 0.36% to $2.4 billion in 2025, then retreated by 0.62% to $2.3 billion in 2026.
• Business Quant data shows IART's Total Non-Current Liabilities at $2.3 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.4 billion in Q3 2025.